BeaconEquity.com releases investment report on PURE

BeaconEquity.com announces an investment report featuring PURE Bioscience (Nasdaq:PURE). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

The full report is available at: http://www.beaconequity.com/i/PURE

Get our alerts BEFORE the rest of the market.  Follow us on Twitter: https://twitter.com/BeaconEquity

PURE Bioscience (PURE) is engaged in the development and commercialization of bioscience technologies. The Company is engaged in developing technology-based bioscience products, including its silver dihydrogen citrate (SDC)-based antimicrobials. SDC is an electrolytically generated source of stabilized ionic silver that can serve as the basis for a range of products in diverse markets. SDC liquid is colorless, odorless, tasteless, non-caustic and formulates well with other compounds.  

Message Board Search for PURE: http://www.boardcentral.com/boards/PURE

In the report, the analyst notes:

"PURE recently reported product revenues for the fiscal second quarter ended January 31, 2010, of $327,000, up from product revenues of $34,800 in the same quarter of the prior fiscal year. The Company reported a net loss of $1,766,200 or $(0.05) per share for the current quarter, improved from a net loss of $2,219,800 or $(0.07) per share in the second fiscal quarter last year.

"PURE recently announced that it has received U.S. Environmental Protection Agency (EPA) registration for its SDC-based disinfectant and food contact surface sanitizer.  The product will be marketed as IV-7 Ultimate Germ Defense for Food Contact Surfaces™ (IV-7) by PURE's sales and marketing representative, Richmont Sciences LLC.  An EPA Category IV disinfectant/sanitizer, IV-7 provides an advantageous combination of high efficacy, low toxicity and efficiency by rapidly eliminating dangerous pathogens, yet no rinse is required."